1. Introduction {#j_sjph-2016-0018_s_001}
===============

Community-associated methicillin-resistant *Staphylococcus aureus* (CA-MRSA) is in Europe associated mainly with the European clone which belongs to the clonal complex (CC) / sequence type (ST) CC80 / ST80 ([@j_sjph-2016-0018_ref_001]-[@j_sjph-2016-0018_ref_006]). This clone was first recognized in Denmark in 1993 ([@j_sjph-2016-0018_ref_007], [@j_sjph-2016-0018_ref_008]) and now CA-MRSA ST80 is widely spread throughout Europe. Epidemiological data presume that this clone originated outside Europe, in the Middle East or in North Africa ([@j_sjph-2016-0018_ref_001], [@j_sjph-2016-0018_ref_003], [@j_sjph-2016-0018_ref_005]-[@j_sjph-2016-0018_ref_006]).

CA-MRSA ST80 is typically resistant to fusidic acid, kanamycin / amikacin and tetracycline ([@j_sjph-2016-0018_ref_001]). In Kuwait, a high-level mupirocin resistant CA-MRSA strain ST80 was found ([@j_sjph-2016-0018_ref_001], [@j_sjph-2016-0018_ref_003], [@j_sjph-2016-0018_ref_005]). The majority of CA-MRSA ST80 isolates carry Pantone-Valentine leukocidine (PVL) genes, staphylococcal cassette chromosome (SCC*mec*) IV and exfoliative toxin type D gene (*etd*) ([@j_sjph-2016-0018_ref_003], [@j_sjph-2016-0018_ref_005]-[@j_sjph-2016-0018_ref_008]). In France and in Croatia, a PVL-negative variant of CA-MRSA ST80 has been described ([@j_sjph-2016-0018_ref_006]). The European clone is associated mainly with skin and soft-tissue infections, but rarely causes other invasive infections such as bacteriemia or meningitis ([@j_sjph-2016-0018_ref_003], [@j_sjph-2016-0018_ref_004]).

We have described the first PVL positive CA-MRSA ST80-IV isolates in Slovenia in four patients hospitalized in one Slovenian hospital in 2003 and 2004 ([@j_sjph-2016-0018_ref_009]). These CAMRSA isolates were associated with skin and soft-tissue infections: one patient developed meningitis. All CAMRSA isolates were typically resistant to beta-lactam antibiotics, kanamycin, tetracycline and fusidic acid and harboured PVL and *etd* genes ([@j_sjph-2016-0018_ref_009]).

In Slovenia, a national monitoring of CA-MRSA strains began in the year 2006. In a national collection obtained at medical microbiology department of the National Laboratory for Health, Environment and Food only CA-MRSA isolates that were resistant to oxacillin and cefoxitin and susceptible to at least two of the following four antibiotics, ciprofloxacin, erythromycin, clindamycin and gentamicin (screening definition of the presumptive CA-MRSA) were included ([@j_sjph-2016-0018_ref_010]-[@j_sjph-2016-0018_ref_012]). Dominant clones identified were ST5, ST45, ST22 and ST398. The authors, in their previous studies, confirmed that genetically heterogeneous CA-MRSA clones circulate in our country ([@j_sjph-2016-0018_ref_011], [@j_sjph-2016-0018_ref_012]).

To our knowledge, no case of death due to CA-MRSA ST80 has been reported in our country. Because ST80 is one of the predominant clones in Europe and because ST80 was confirmed in Slovenia in the years 2003 and 2004, the aim of the current study was to investigate the presence of the CA-MRSA ST80 strain among human samples in our country. The study describes the detailed characterization by epidemiological investigation, antimicrobial resistance pattern, toxin gene and molecular profiling.

2. Methods {#j_sjph-2016-0018_s_002}
==========

2.1. MRSA Surveillance in October 2013 {#j_sjph-2016-0018_s_002_s_001}
--------------------------------------

In October 2013, a blood culture from a 69-year-old female yielded MRSA. She had a transsphenoidal biopsy of a large parasellar meningioma and was prior to surgery without health-care risk factors. Subsequent screening swabs from the nose and tracheal aspirate yielded CAMRSA. In an attempt to identify the source of the CAMRSA, an epidemiological investigation was started, and surveillance swabs (throat, nose, groin) were obtained from all her available household members, nose swabs from domestic animals (pigs, goats, poultry) and dust samples from the farm environment.

2.2. Retrospective Analyses of CA-MRSA Isolates Collected in a National Collection of Presumptive CA-MRSA Isolates {#j_sjph-2016-0018_s_002_s_002}
------------------------------------------------------------------------------------------------------------------

We reviewed presumptive CA-MRSA isolates in the strain collection database from 2006 to 2013. Only CA-MRSA that belonged to ST80 were included in further analyses.

2.3. Patients' Data and Case Definition {#j_sjph-2016-0018_s_002_s_003}
---------------------------------------

A trace back epidemiological investigation for each patient with CA-MRSA ST80 isolate was performed. Several features were collected from the medical report: patient characteristics (demographic data, clinical data), treatment and outcome. A CA-MRSA was defined as a strain isolated from ambulatory patients or from inpatients within 48 hours of hospital admission, with no risk factors for nosocomial acquisition in the previous year, such as colonisation or infection with MRSA, hospitalization or residence in long-term care facilities, surgery or use of an indwelling catheter. All other isolates were considered as HA-MRSA.

2.4. Bacterial Isolates and Antimicrobial Susceptibility Testing {#j_sjph-2016-0018_s_002_s_004}
----------------------------------------------------------------

All *S. aureus* isolates were identified by mass spectrometry (MALDI-TOF, Biotyper, Bruker Daltonic GmBH, Bremen, Germany). The susceptibility of CA-MRSA isolates was tested against 16 antimicrobial agents using the disk diffusion method according to the guidelines of the Clinical Laboratory Standard Institute (CLSI) ([@j_sjph-2016-0018_ref_013]). The antibiotics tested were penicillin, cefoxitin, vancomycin, gentamicin, tobramycin, kanamycin, erythromycin, clindamycin, tetracycline, ciprofloxacin, trimethoprimsulfamethoxazole, chloramphenicol, rifampin, linezolid, mupirocin and fusidic acid (BD, Maryland, USA). Minimal inhibitory concentration (MIC) determination of oxacillin was performed using the E-test (bioMerieux, Marcy I'Etoile, France).

2.5. Molecular Characterization {#j_sjph-2016-0018_s_002_s_005}
-------------------------------

MRSA isolates were screened by PCR (polymerase chain reaction) for the PVL encoding lukS-PV and lukF-PV genes and *mec* A gene using Genotype Staphylococcus (Hain Lifesciences, Germany). The identification of the SCC*mec* types and the presence of exfoliative genes (*eta, etb, etd*) was performed using primers as described previously ([@j_sjph-2016-0018_ref_014]-[@j_sjph-2016-0018_ref_015]). MRSA isolates with a positive phenotypic screening pattern were characterized by *spa* typing according to a method described previously ([@j_sjph-2016-0018_ref_016]). Multilocus sequence typing (MLST) was performed as described by Enright et al ([@j_sjph-2016-0018_ref_017]). ST designations were assigned by the MLST database (available from: <http://www.mlst.net>).

3. Results {#j_sjph-2016-0018_s_003}
==========

3.1. Isolate Characteristics {#j_sjph-2016-0018_s_003_s_001}
----------------------------

Between 2006 and 2013, among the 385 CA-MRSA isolates included in our national collections, only 2 (0.5%) were identified with resistance to penicillin, cefoxitin, kanamycin, tetracycline and fusidic acid and susceptibility to vancomycin, gentamicin, tobramycin, erythromycin, clindamycin, ciprofloxacin, trimethoprimsulfamethoxazole, chloramphenicol, rifampin, linezolid and mupirocin.

Both CA-MRSA isolates had MIC of oxacillin between 16-64 mg/L and MIC of vancomycin 2 mg/L. PVL and *mec* A genes and SCC *mec* IV were confirmed in both CA-MRSA isolates. Both CA-MRSA isolates were associated to ST80.

3.2. Clinical Characteristics of MRSA Infection {#j_sjph-2016-0018_s_003_s_002}
-----------------------------------------------

One CA-MRSA isolate was isolated from a wound swab and one from blood culture. No CA-MRSA ST80 were found between 2006 and 2012. Epidemiological investigations showed that both CA-MRSA ST80 isolates were detected in the year 2013, in different regions of Slovenia, and no connection between them was found.

First CA-MRSA ST80 was confirmed in a 47-year-old male. The patient had no health-care associated risk factors for MRSA colonization or infection, and no surveillance swabs for MRSA were taken. He had clinical signs of a wound infection and bacterial sampling was performed in a surgical emergency department. Initial antibiotic therapy was inappropriate (amoxicillin/clavunate) and infection was cured with clindamycin.

Epidemiological investigation showed that the second CA-MRSA ST80 strain was isolated from a 69-year-old female. The patient was previously healthy with no known risk factors for MRSA infection. Upon admission for transsphenodial biopsy of a large parasellar meningioma, no surveillance swabs for MRSA were taken. Infection of purulent meningitis occurred thirteen days after the first admission. A head CT scan showed inflammation in the region where the biopsy had been performed and a lumbar puncture confirmed meningitis. Intravenous therapy with cefepime (2 g/6 hour) and vancomycin (3 g/day) was started. She was intubated and mechanically ventilated. The patient remained febrile despite the treatment and vancomycin was changed to daptomycin (10 mg/kg). Clindamycin was added, because she also developed pneumonia. Cerebrospinal fluid remained sterile but eubacterial PCR yielded *S. aureus*. Transesophageal Echo was negative. Despite several cleanings of the nose and paranasal sinuses the control CT scan revealed local deterioration. New ischaemic brain lesions were also seen. Ethmoidectomy and meatotomy of paranasal sinuses were performed. Patient slowly improved. Upon waking up, she started to bleed massively from both nostrils. Nasal tamponade was inserted and she received a transfusion of red blood cells. The massive bleeding repeated itself and she was unsuccessfully resuscitated. She died 25 days after the first surgery ([Table 1](#j_sjph-2016-0018_tab_001){ref-type="table"}).

3.3. MRSA Surveillance in October 2013 {#j_sjph-2016-0018_s_003_s_003}
--------------------------------------

All human, animal and farm environmental samples tested in an association with 69-year-old female patient were MRSA negative.

4. Discussion {#j_sjph-2016-0018_s_004}
=============

The frequency of CA-MRSA ST80 varies from \< 5% in Spain to 92% in Greece ([@j_sjph-2016-0018_ref_001]). A high frequency of ST80 strain is also documented in Kuwait, Lebanon, Israel, Egypt, Algeria and Tunisia, suggesting their clonal origin ([@j_sjph-2016-0018_ref_001], [@j_sjph-2016-0018_ref_004], [@j_sjph-2016-0018_ref_006]). According to the authors, CA-MRSA ST80 is also circulating in our neighboring countries (Italy, Austria, Croatia) ([@j_sjph-2016-0018_ref_006]), but surprisingly CA-MRSA ST80 is not very common in Slovenia. To date, infections caused by CAMRSA ST80 seemed to be sporadic cases. In our previous study that lasted from 2003 to 2004, we confirmed CAMRSA ST80 isolates in four hospitalized patients following necrotizing soft tissue infection, purulent abscesses and epidural catheter infection and meningitis ([@j_sjph-2016-0018_ref_009]). Between 2006 and 2013, we found only 2 (0.5%) CA-MRSA ST80 strains among 385 presumptive CA-MRSA isolates. Both CA-MRSA ST80 isolates were confirmed in the year 2013, in different regions of Slovenia, and no epidemiological connections between these two infections were found. According to our epidemiological investigation, both of the patients with CA-MRSA infection were in good health prior to their infections. The first patient had a wound infection, without health-care associated risk factors, and no surveillance samples for MRSA carriage were taken. The patient was treated in a surgical emergency department without hospital admission. However, it cannot be excluded that the patient was colonized with CA-MRSA prior to surgical procedure.

###### 

Phenotypical, genotypical and epidemiological characteristics and clinical data from patients infected with CA-MRSA ST80 strain in Slovenia between 2006 and 2013.

  Characteristic                                                 
  ------------------------------------------- ------------------ -----------------------------------
  Gender                                      M                  F
  Age (years)                                 47                 69
  Diagnosis at hospital admission             Abscessus glutei   Meningeoma
  Source of isolates                          Wound swab         Blood cultures, tracheal aspirate
  Type of infection                           SSTI               Sepsis and meningitis
  Outcome                                     recovered          death
  Risk factors for MRSA colonization                             
   History of MRSA infection / colonization   No                 No
   Surgery in the past year                   No                 Yes
   Hospitalization in the past year           No                 Yes
   Residence in a day care                    No                 No
  Resistance pattern                          P, OX, TE, FA, K   P, OX, TE, FA, K
  MIC of oxacillin (mg/L)                     16                 64
  Typing                                                         
   *SCCmec* type                              IV                 IV
   *spa* type                                 t044               t044
   MLST (ST)                                  80                 80
  Toxin gene profile                                             
   PVL                                        \+                 \+
   etd                                        \+                 \+

Legend: M male, F female, SSTI skin and soft tissue infection, MIC minimal inhibitory concentration, PVL Panton-Valentine Leukocidin, MLST multi locus sequence typing, ST sequence type, SCC*mec* staphylococcal cassette chromosome *mec*, SCC *mec* type IV, *etd* exfoliative toxin gene type D, FA fusidic acid, K kanamycin, Te tetracycline, P penicillin, OX oxacillin (cefoxitin)

The second patient developed a serious infection caused by CA-MRSA ST80 after surgery and no surveillance samples for CA-MRSA carriage were taken prior to surgery. CA-MRSA was isolated from the patient's blood culture, tracheal aspirate, nose swab and cerebrospinal fluid. In an attempt to identify the source of the CA-MRSA, surveillance swabs were taken from the patient's husband. Because the patient was living on a farm, nasal swabs were also taken from clinically healthy piglets and dust samples from their environment. All samples tested were MRSA negative. The major limitation of our study was the lack of extensive staff and hospital environment screening. Therefore, the source of the patient's CA-MRSA isolate remained unclear. Based on clinical data, epidemiological investigation and lack of health-care risk factors, we predicted that CA-MRSA in the 69-year-old female was transmitted by the hands of the personnel temporarily colonized with bacteria or contaminated medical equipment during surgery, or the patient was colonized with CA-MRSA in the community. Upon confirmation of CA-MRSA isolate in the patient's specimens, the standard and contact precautions for preventing MRSA transmission in hospital were introduced. Despite appropriate antibiotic therapy, the patient died and, to our knowledge, this was the first documented death caused by CA-MRSA ST80 in Slovenia.

According to our results, we suspect that infections caused by CA-MRSA ST80 in Slovenia remain relatively low and are underestimated. Firstly, the epidemiological investigation of a patient's infections is performed only when atypical MRSA isolate is recovered from patient's specimens, such as resistance to tetracycline, which is associated with LA-MRSA ([@j_sjph-2016-0018_ref_004]). Secondly, phenotypically confirmed MRSA is not routinely tested for genotypic characteristics, such as spa type or ST. Thirdly, no information is available about the occurrence of CA-MRSA among healthy carriers that are a potential source of infections in the community. Finally, clinical samples are not routinely cultured, but only upon inappropriate therapy or progressing infection. In conclusion, we also speculate that migration will likely increase CA-MRSA carriage and infections in the near future also in our country.

In 2014, on behalf of the National Institute of Public Health of Slovenia, two surveillance programs were assigned to monitor CA-MRSA and LA-MRSA incidence on the national level. To date, CA-MRSA infections caused by the ST80 strain are rare in Slovenia, but molecular testing, epidemiological investigations and surveillance studies of CA-MRSA and LA-MRSA are needed to control and monitor these pathogens that are considered a public health threat all over the world.
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